SARASOTA, Fla., May 18 /PRNewswire-FirstCall/ -- Industrial Biotechnology Corporation (IBC), a company dedicated to new technologies and innovations in the chemicals industry, announced today that Dr. John Leffingwell, a well known industry expert specializing in the flavor and fragrance market place, has joined IBC's Strategic Advisory Board. This appointment will combine Dr. Leffingwell's industry and technical expertise with IBC's proprietary technologies and intellectual property in the emerging field of biologically produced chemicals.
"John has the knowledge, relationships and expertise in the 16 billion dollar flavor and fragrance industry that will accelerate IBC's ability to successfully commercialize its technology," stated Gary Howell, Vice President of Business Development for IBC. "His many years in the industry will greatly enhance our time to market and ability to secure joint venture partnerships with flavor and fragrance suppliers, manufactures and distributors."
"Leffingwell & Associates is honored to join forces with IBC and be at the forefront of this pioneering science," said John Leffingwell, President of Leffingwell & Associates. "The applications of IBC's Designer Enzyme and Biosynthesis Technologies have the ability to reinvent the chemical industry as we know it today. Through this partnership, we plan to be a valuable resource to IBC by providing key market data, chemical and compound information and assisting in developing additional sales and distribution partnerships."
About Leffingwell & Associates and Dr. John C. Leffingwell
Leffingwell & Associates is engaged in providing contract R&D and technical management consulting with specialization in flavor applications & development. Leffingwell & Associates has a proven record of success in the development of new products. Since 1985, over 75 products developed in their laboratories have been introduced nationally or in international markets. Some of their clients have include Haagen-Dazs, Burger King, Slim-Fast, The Kellogg Company, Sunkist Growers, Arthur D. Little and a number of international companies in the field of flavor R&D. In late 1989, Leffingwell & Associates introduced FLAVOR-BASE, which has now become the world's best selling flavor database system -- a product used by nearly all of the world's largest manufactures of flavors and fragrances, foods and beverages.
Dr. Leffingwell was a senior research chemist with the Glidden company involved in terpene research and essential oil reconstitution. He held various technical management positions with RJR Industries, including being head of flavor R&D and Vice President of their flavor manufacturing subsidiary (Aromatics Intl.). During this period he developed a synthesis for L-menthol and pioneered development of the production of Clary sage oil and Basil oil in North Carolina. Dr. Leffingwell was Senior Vice President of Sunkist Soft Drinks and then served with Del Monte as Vice President, Worldwide Technical Operations for Canada Dry/Sunkist/Hawaiian Punch. Since 1985, Dr. Leffingwell has been President of Leffingwell & Associates
He received his B.Sc. from Rollins College and M.Sc. & Ph.D. from Emory University. He did postdoctoral work as an NIH Fellow at Columbia University. Dr. Leffingwell has been the recipient of The Rollins College Award for Distinguished Alumni in Science as well as the Philip Morris Award for Distinguished Achievement in Science. He is the author or co-author of over 100 patents, books and publications. http://www.leffingwell.com
About Industrial Biotechnology Corporation
Industrial Biotechnology Corporation (IBC) commercializes proprietary technologies and intellectual property in the emerging field of biologically produced chemicals. We believe these technologies enable IBC to more efficiently manufacture high-value chemicals at significantly lower costs, with a higher purity and with a substantially lower environmental impact than traditional methods. Through licensing, partnerships, and direct sales via multiple distribution channels to several industries, IBC seeks to bring to market new and established chemicals that are in high demand for use in industrial, flavors, fragrances, fine chemicals, pharmaceutical, agricultural, environmental and bio-energy applications. IBC's pioneering and state-of-the- art biological production methods can replace large manufacturing facilities, many of which employ hazardous processes and toxic materials in their chemical production. These innovative methods involve fewer production steps, and through the use of "designer" enzymes and proprietary production systems, may enable IBC to produce greater yields of high-purity, natural compounds at significantly lower costs. We believe these processes can be readily scaled up to large commercial production levels. The company has assembled a team of leading scientists, management and industry leaders to implement these new technologies. IBC has a comprehensive technology and licensing acquisition strategy, and seeks to establish research and development partnerships with leading universities and corporations in the industrial biotechnology field to develop commercially viable, biological-based solutions and related intellectual property and patents. For more information about Industrial Biotechnology Corporation, please visit its website at http://www.industrialbiotechnology.com .
Forward-Looking Statements
Certain matters discussed in this press release are "forward-looking statements." These forward-looking statements can generally be identified as such because the context of the statement will include words such as "expects," "should," "believes," "anticipates" or words of similar import. Similarly, statements that describe Industrial Biotechnology Corporation's future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of Industrial Biotechnology Corp., as appropriate, which could cause actual results to differ materially from those currently anticipated. Although Industrial Biotechnology Corp. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, they cannot give any assurance that their expectations will be attained. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Certain factors could cause results and conditions to differ materially from those projected in these forward-looking statements, and some of these factors are discussed below. These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. These forward-looking statements are only made as of the date of this press release and Industrial Biotechnology Corporation does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Industrial Biotechnology CorporationCONTACT: Jack Hensley, Manager, Public & Investor Relations, IndustrialBiotechnology Corporation, +1-941-925-2500, orjhensley@industrialbiotechnology.com
